Key result
Pharmacologic and non-pharmacologic treatments, including ACE inhibitors, beta-blockers, and device therapies, significantly improve survival and symptoms in patients with heart failure with reduced ejection fraction.
This review provides an updated overview of evidence-based pharmacologic and device therapies for managing heart failure with reduced ejection fraction.
Supports GDMT in HFrEF; confirms prior evidence yet leaves open optimal sequencing with novel agents.
The prevalence of heart failure (HF) has been steadily increasing and it now creates an enormous social and economic burden. HF is a syndrome characterized by a high mortality rate, frequent hospitalization, a reduced quality of life, and a complex therapeutic regimen. In the last three decades, major progress in both the diagnosis and management of HF has taken place, and the pharmacologic and non-pharmacologic advances have led to a significant improvement in survival and symptoms in HF patients. After an accurate diagnosis, a proper HF management plan requires a multi-level team approach comprised of the correct combination of drug therapy, device therapy, and surgery, including heart transplantation. In this review, we focused on the pharmacologic and non-pharmacologic treatment strategies for HF with reduced ejection fraction. The goal was to develop treatment guidelines based on significant evidence derived from large clinical trials. (Korean J Med 2015;88:127-134)
No takes yet. Share an insight, caveat, or question.
Park et al. (2015) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Pharmacologic and non-pharmacologic treatments was evaluated. Pharmacologic and non-pharmacologic treatments, including ACE inhibitors, beta-blockers, and device therapies, significantly improve survival and symptoms in patients with heart failure with reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: